Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
Jonathan C. Poe, Wei Jia, Julie A. Di Paolo, Nancy J. Reyes, Ji Yun Kim, Hsuan Su, John S. Sundy, Adela R. Cardones, Victor L. Perez, Benny J. Chen, Nelson J. Chao, Diana M. Cardona, Daniel R. Saban, Stefanie Sarantopoulos
Jonathan C. Poe, Wei Jia, Julie A. Di Paolo, Nancy J. Reyes, Ji Yun Kim, Hsuan Su, John S. Sundy, Adela R. Cardones, Victor L. Perez, Benny J. Chen, Nelson J. Chao, Diana M. Cardona, Daniel R. Saban, Stefanie Sarantopoulos
View: Text | PDF
Research Article Immunology Transplantation

SYK inhibitor entospletinib prevents ocular and skin GVHD in mice

  • Text
  • PDF
Abstract

Graft-versus-host disease (GVHD) is a major complication of hematopoietic stem cell transplantation (HCT). The tyrosine kinase SYK contributes to both acute and chronic GVHD development, making it an attractive target for GVHD prevention. Entospletinib (ENTO) is a second-generation highly selective SYK inhibitor with a high safety profile. Potential utility of ENTO as GVHD prophylaxis in patients was examined using a preclinical mouse model of eye and skin GVHD and ENTO-compounded chow. We found that early SYK inhibition improved blood immune cell reconstitution in GVHD mice and prolonged survival, with 60% of mice surviving to day +120 compared with 10% of mice treated with placebo. Compared with mice receiving placebo, mice receiving ENTO had dramatic improvements in clinical eye scores, alopecia scores, and skin scores. Infiltrating SYK+ cells expressing B220 or F4/80, resembling SYK+ cells found in lichenoid skin lesions of chronic GVHD patients, were abundant in the skin of placebo mice but were rare in ENTO-treated mice. Thus, ENTO given early after HCT safely prevented GVHD.

Authors

Jonathan C. Poe, Wei Jia, Julie A. Di Paolo, Nancy J. Reyes, Ji Yun Kim, Hsuan Su, John S. Sundy, Adela R. Cardones, Victor L. Perez, Benny J. Chen, Nelson J. Chao, Diana M. Cardona, Daniel R. Saban, Stefanie Sarantopoulos

×

Figure 8

ENTO reduces skin GVHD in +Spl mice.

Options: View larger image (or click on image) Download as PowerPoint
ENTO reduces skin GVHD in +Spl mice.
(A) Representative images of skin s...
(A) Representative images of skin sections obtained from the upper backs of mice from the indicated groups stained with H&E (top) and Masson’s Trichrome (bottom). Stars indicate regions of increased collagen density, indicative of GVHD-mediated fibrosis, in +Spl/placebo mice. Arrows indicate hair follicles, which were largely absent in +Spl/placebo mice. Scale bar: 115 μm. (B) Various skin disease criteria from all mice in each HCT group (n = 9–10/group), scored in a masked fashion by an expert pathologist specializing in GVHD-mediated skin disease. Scoring criteria were as follows: dermis (0, normal; 1, mild increased collagen density; 2, marked increased collagen density); hair follicles (0, normal number of approximately 5 per linear millimeter; 1, between 1 and 5 follicles per linear millimeter; 2, <1 follicle per linear millimeter); epidermis (0, normal; 1, interface damage in <20% of section with occasional necrotic keratinocytes; 2, widespread interface damage (>20% of section); inflammation (0, none; 1, focal infiltrates; 2, widespread infiltrates). Each symbol represents an individual mouse. Bars indicate the median ± range. Total skin score represents the sum of all above criteria for each mouse. Statistical analysis was performed by 1-way ANOVA with Tukey’s multiple comparisons test (GraphPad Prism). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts